AzTrials
AzTrials

HypothyroidismNCT05015725

The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients

An observational study of Hypothyroidism, run by Semmelweis University at 1 site in Hungary.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate the relationship between serum rT3 (serum reverse triiodothyronine) concentrations, T3/T4 (triiodothyronine/thyroxine) ratio, and persistent symptoms /quality of life in treated hypothyroid patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hypothyroidism
What is being tested?
Quality of life assessment, biochemical measures
How many people
262 participants
Where
1 siteHungary
Study dates
1 Aug 2021to 31 Aug 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Adult patients treated for hypothyroidism with levothyroxine substitution.

Who may be able to join

  • At least 18 years of age, inclusive, at the time of signing informed consent form.
  • Hypothyroidism treated for >2 years
  • TSH stable between 0.4 and 4.0 mIU/L for the past 6 months (at least 2 measurements)

Who cannot join

  • Abnormal TSH on screening
  • Unwilling or unable to participate/sign informed consent
  • Changes in thyroxine dose or any other medication in the previous month
  • Severe obesity (BMI [body mass index] >35kg/m2)
  • Other significant comorbidity:
  • History of ischaemic heart disease, valvular defect, stent placement, heart failure, stroke or TIA (transient ischemic attack)
Show all 11Show fewer
  • Diabetes mellitus under OAD (oral antidiabetic drug) or insulin treatment
  • eGFR (estimated glomerular filtration rate) <60ml/min at screening, calculated by EPI formula
  • History of liver disease, AST/ALT>3 times normal or GGT (gamma-glutamil transferase) >2 times normal or hyperbilirubinaemia at screening
  • Systemic autoimmune condition currently under treatment (RA [rheumatoid arthritis], lupus, systemic sclerosis etc.)
  • Active malignancy

Trial locations and contacts

1 site in 1 country.

Hungary1 site
  • Semmelweis University - Departement Medicine and Oncology

    Budapest, 1083

Other trials in Hungary

About this study

Official title: A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients

The aim of this study is to evaluate the relationship between serum rT3 (serum reverse triiodothyronine) concentrations, T3/T4 (triiodothyronine/thyroxine) ratio, and persistent symptoms /quality of life in treated hypothyroid patients.

Investigators are going to measure TSH (thyroid stimulating hormone), free-T3, free-T4, reverse-T3 levels, biochemical markers of hypothyroidism and quality of life (assessed by validated questionnaires).

Read the detailed description

Rationale: L-thyroxin (T4) substitution is the mainstay of treatment for hypothyroidism irrespective of disease origin. In a subset of patients with hypothyroidism however an inadequate peripheral T4->T3 conversion is hypostasized by some authors. This is speculated to lead to tissue level hypothyroidism and persistent symptoms even with adequate T4 replacement. As a potential pathogenetic mechanism, the inborn or acquired defect of peripheral deiodinases, decreased T3 and increased rT3 production is suggested.

Few results support this hypothesis. A decreased T3/T4 ratio has been reported in some post-surgical hypothyroid patients, while a few studies patient show increased patient satisfaction with combined T4+T3 substitution. However these differences have not been shown to be significant in large meta-analyses.

Due to the lack of convincing evidence current guidelines advocate against both routine rT3 measurement and T3 substitution. However in recent years, rT3 measurement and T3 supplementation has been steadily gaining popularity amongst some medical and functional medicine practitioners. Recent publications estimate order volume for rT3 tests in the US to be over 1 million per year. Thus, despite several decades of experience and multiple trials, the role of liothyronine (T3) substitution remains somewhat controversial.

The relationship between rT3 levels, T3/T4 ratio, quality of life and persistent symptoms of hypothyroidism in patients treated with adequate thyroxine doses has not been previously assessed.

A significant association of this nature would suggest the possibility of decreased peripheral T4->T3 conversion in some patients leading to worse treatment outcomes. A lack of relationship would further discredit the above detailed theories and could potentially help reduce the inadequate use of T3 substitution in patients.

Study population: Patients treated for hypothyroidism with no significant comorbidities are to be enrolled. Sample size calculations show adequate statistical power with over 150 participants. Based on the number of hypothyroid patients at our outpatient clinic, a sample size of 300-350 patients can reasonably be expected.

Schedule of activities: All study related procedures are performed during a single visit. These include recording of basic anthropometric data, a single draw of blood, and administration of psychological questionnaires. Laboratory tests include comprehensive thyroid function testing (TSH, T3, FT3, FT4, aTPO [anti-thyroperoxidase antibody]) with the addition of rT3 measurement. Less specific markers, associated with hypothyroidism are also assessed. These include serum cholesterol, CK (creatin-kinase), GOT/ASAT (aspartate-aminotransferase), GPT/ALAT (alanine-aminotransferase), creatinine and sodium levels. Psychological tests administered at the visit include ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.

Statistical analysis: Statistical methods for this study possibly include correlation analysis, linear and logistic regression.

Objectives and endpoints: Current understanding of hypothyroidism and thyroid hormone replacement imply that treatment with thyroxine doses that are sufficient to the normalize TSH lead to adequate tissue T3 levels and euthyroid state in the whole body. An association however between quality of life and rT3, levels or T3/T4 ratio could point out patients that could potentially benefit from additional T3 replacement.

Conditions
Hypothyroidism
Being tested
Quality of life assessment, biochemical measures
Keywords
hypothyroidism, reverse T3, quality of life
Medical subject headings
Hypothyroidism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Quality of life assessment, biochemical measuresDiagnostic test

    Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.

    Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels.

Study groups in NCT05015725
Study groupRoleWhat they receive
Treated hypothyroidismPatients with treated hypothyroidism
Receives: Diagnostic Test: Quality of life assessment, biochemical measures

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Association between rT3 level and quality of life

    Result of linear regression for evaluating the possible relation between serum reverse-T3 level and quality of life (QoL). For QoL assessment we are going to use the total points achieved on ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) tests.

    Measured: baseline

  2. Association between rT3 level and SASS result

    Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of Somatosensory Amplification Scale (SASS) questionnaire.

    Measured: baseline

  3. Association between rT3 level and ThySRQ result

    Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThySRQ questionnaire.

    Measured: baseline

  4. Association between rT3 level and ThyDQol result

    Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThyDQol questionnaire.

    Measured: baseline

Secondary outcomes (6)
  1. Association between rT3 and LDL-cholesterol level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and LDL-cholesterol level.

    Measured: baseline

  2. Association between rT3 and CK level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and creatin-kinase level.

    Measured: baseline

  3. Association between rT3 and GOT/ASAT level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and GOT/ASAT level.

    Measured: baseline

  4. Association between rT3 and GPT/ALAT level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and GPT/ALAT level.

    Measured: baseline

  5. Association between rT3 and eGFR level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and eGFR level (eGFR will be calculated by using EPI formula).

    Measured: baseline

  6. Association between rT3 and sodium level

    Result of linear regression for evaluating the possible relation between serum reverse-T3 and sodium level.

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Aug 2021
  2. Study start1 Aug 2021
  3. Primary completion31 Aug 2022
  4. Study completion31 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
262 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05015725
Sponsor's protocol ID
RT3QoLSE
Status last verified
Oct 2022
First submitted
30 Jun 2021
Last updated
12 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hypothyroidism, run by Semmelweis University at 1 site in Hungary.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Association between rT3 level and quality of life (time frame: baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in